US 7569580
Heterotricyclic compounds for use as HCV inhibitors
granted A61PA61P31/12
Quick answer
US patent 7569580 (Heterotricyclic compounds for use as HCV inhibitors) held by Rigel Pharmaceuticals, Inc. expires Mon Jul 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Aug 04 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61P, A61P31/12